The Current Problem
Cell culture media is the foundation of modern biotechnology — yet it remains a bottleneck
Traditional Methods of Media Design
Low-throughput
Slow
No complex biological interactions
As a result, cells often underperform, costs remain high, and time-to-market is delayed across sectors like cell therapy, immunotherapy, and cultivated meat.
A smarter, faster solution is long overdue.
Our Technology
HiDiNeu, our proprietary algorithm, is tackling cell culture media complexity without the cost.
By combining evolutionary computing with machine learning, HiDiNeu rapidly identifies optimal combinations across 25+ media components from scratch—requiring fewer experiments, reducing costs, avoiding bias, and delivering more biologically relevant results. It adapts to any measurable cell phenotype, from growth to differentiation and function.
HiDiNeu is purpose-built for speed, accuracy, and versatility in real biological systems.
Our Advantages
Smarter Algorithm
HiDiNeu optimizes 25+ ingredients at 5 dose levels with fewer iterations and higher accuracy than traditional DoE or black-box AI models.
Proven Science
Our platform has demonstrated real-world success, outperforming commercial standards for in vitro cardiomyocyte maturation.
Flexible Collaboration Models
Whether building in-house IP or co-developing with partners, we tailor our approach to maximize biological relevance and commercial value.
Our Process
HiDiNeu designs optimized cell culture media in weeks—not years. We start with your cell type and desired outcome. HiDiNeu maps hundreds of possible ingredient combinations and strategically selects an initial set of formulations for lab testing. Performance data feeds back into the algorithm, which learns, evolves, and generates improved candidates. Within as few as 26 days, we deliver 5-10 top-performing formulations, each generating new IP.
Our Pipeline
DISCOVERY
FORMULATION
R&D use
VALIDATION
COMMERCIALIZATION
PRODUCT
-
Our first AI‑optimized formulation, BIQ-001, was developed using the HDDE algorithm—the precursor to HiDiNeu. It outperforms leading commercial R&D media across multiple measures of cardiomyocyte maturity (morphology, marker expression, metabolic shift, electrophysiology). The formulation is exclusively licensed to Axol Bioscience and is now available as MyoMax™ for research use.
Cell Therapy
-
Building on BIQ‑001, we are using HiDiNeu to design a next‑generation, chemically defined medium that produces human pluripotent stem cell‑derived cardiomyocytes (hPSC‑CMs) mature enough for safe, effective transplantation. This GMP‑compatible formulation will enable cell therapy companies to remuscularize damaged hearts without the risk of arrhythmias. Top‑hit formulations are expected by late 2027.
-
HiDiNeu is a platform technology that can optimize media for any cell, and BIQ‑003 represents our expanding pipeline beyond cardiac applications. Current collaborations include T‑cell expansion, where serum‑free formulations outperform traditional media and are already in licensing discussions.
Interested in our Technology?
At boutIQ solutions Inc, we are transforming how custom cell culture media is developed, using powerful AI to drive faster and smarter biological discovery. We’re excited to explore new horizons together!